Blog
Log In
Contact us

Tag: life sciences

Categories
News Product

OMNY Health launches new GI real-world data solutions in partnership with leading US gastroenterology practices

new GI real-world data solutions

OMNY Health’s GI partnerships are a pivotal step in its mission to deliver data and insights to accelerate life-changing innovation. With a focus on catalyzing research and improving outcomes, OMNY aims to make a tangible difference for the millions of individuals in the US impacted by gastroenterology diseases

ATLANTA, GA, April 22, 2024 – OMNY Health is pleased to announce its partnership with the nation’s leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research. Over 5,000 GI providers serving more than 10 million patients are now part of OMNY’s research network, representing care delivery by over 380,000 providers and 75 million patients across the US. The focus on GI practice data is a notable expansion to OMNY’s real-world data ecosystem, which works with providers to support compliant research partnerships at scale. OMNY works with the health systems to enable insights on patient population characteristics, care delivery patterns, and treatment outcomes based on data extracted from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY’s solutions deliver valuable information on disease severity, rationale behind treatment decisions, treatment efficacy, and impact of social determinants on treatment selection and disease progression. By integrating disparate EHRs into unified, de-identified research data products, OMNY offers researchers and providers the breadth and depth of information needed to address their biomedical and population health research questions.

“United Digestive remains committed to offering our patients the most suitable and cost- effective healthcare solutions. Our dedication to delivering best-in-class GI care is intricately linked with our data-driven approach,” says United Digestive’s Chief Medical Officer, Dr. John Suh. “We are thrilled to announce our partnership with OMNY Health, which allows us to drive further insights from our data to advance patient care.”

“As Florida’s leading gastroenterology provider, Borland Groover’s mission is to provide exceptional care and improve the lives of our patients. Achieving this objective requires a deep understanding of our patients, patterns of care, outcomes, and opportunities for further improvement through data analysis,” said Borland Groover’s CEO, Dr. Kyle Etzkorn. “Our collaboration with OMNY not only aligns with our mission, but it also presents avenues to identify and pursue future opportunities for elevating GI patient care.”

“Enhancing patient care isn’t just a goal; it’s our responsibility, guided by the personal experiences of every patient we serve. Each piece of patient data is not just a statistic; it is a pathway to better outcomes, a testament to our commitment, and a source of inspiration for ongoing progress” said Christa Newton, MBA, CEO, OneGI. “We are excited to partner with OMNY as a tangible step in realizing these guiding principles for the benefit of our patients.”

“It is important to One GI that our patients are represented when it comes to emerging research, care improvement initiatives, and best in class care. Our partnership with OMNY helps ensure our providers have the data and support they need to deliver easy to access exceptional GI care.” – Dr. Michael Dragutsky, Founder, Chairman, OneGI. Key populations available in the GI specialty offerings are aligned with the significant research and development efforts underway in gastroenterology, including ulcerative colitis, Crohn’s disease, celiac disease, short bowel syndrome, reflux disorders, and many others. Like other OMNY Health specialty-focused solutions, the GI offering includes information covering pharmacy orders, lab and diagnostic test results, comorbidities, symptom checklists, and provider clinical assessment scores. “We are thrilled to welcome our new gastroenterology providers to our network. Over the past two years, we have made great strides connecting researchers and providers participating in our dermatology and ophthalmology research networks. We look forward to building on that impact in the field of gastroenterology,” said Mitesh Rao, MD, CEO, OMNY Health.

About OMNY Health

OMNY Health connects the healthcare ecosystem through data and insights to transform healthcare delivery, improve clinical outcomes, and address patients’ unmet needs.   The OMNY platform serves as a centralized resource for healthcare stakeholders to participate in data sharing and research services at scale, fueling innovation where patients need it the most. For more information, go to www.marketing-dev.omnyhealth.com.

MEDIA INQUIRIES: media@omnyhealth.com 

Categories
Editorial

Linking Real-World Clinical Data with Medical Device Data to Demonstrate Device Value

Clinical Data, Medical Device

Real-World Data in the Medical Device Market

Many life sciences organizations are focused on harnessing real-world data (RWD) capabilities to inform every part of the drug development product life cycle. The same types of RWD can, and should, be applied to innovation around the development and measurement of the effects of medical devices. RWD derived from healthcare sources, such as electronic health records, provides insights into the burden of disease, and after a device market launch, provides insights into competitive stance, safety, efficacy, and outcomes. Traditionally, these types of analyses have been difficult to perform for medical devices because the specific details surrounding the medical device make, model, and manufacturer used in procedures are often buried in the electronic health record or other IT systems, and historically have not been collected uniformly. 

Medical Devices in the Real World

Medical Devices have become a critical part of a patient’s daily life, and how patients interact with these devices can tell us a lot about their effectiveness. From joint replacements to life-saving arterial stents and pacemakers, device manufacturers are interested in the benefit-risk profiles to inform future device modifications and technological advancements, Providers can glean important evidence for the clinical effectiveness of these devices, helping to inform what devices to use in their procedures. 

Medical device manufacturers are motivated to invest in new strategies to support success. According to McKinsey, despite a period of growth from 2012 through 2019, S&P medical device investments slowed during the pandemic. Recently, however, signs have been promising; in 2023, the U.S. approved more novel medical technologies than in any single year before, and revenue growth rates are starting to stabilize to pre-pandemic levels. 

Aggregation of RWD to Inform Device Safety and Evidence for Effectiveness

Using relevant and reliable RWD is important for generating RWE to understand and regulate medical device usage and safety. To get a complete picture of the patient’s use and interaction with a medical device, RWD from clinically relevant sources is required to give a holistic view of the clinical experience both before device implant/initiation and after usage has been initiated. The ability to combine disparate data from multiple sources and care settings is where OMNY Health excels. 

The OMNY Health Medical Device Data Advantage

OMNY Health’s Medical Device product offering is a best-in-class view into the healthcare industry’s use of medical devices in patients. Our Medical Device offering is constructed directly from our health provider data sets, with precision down to the patient encounter level. Utilizing the Unique Device Identifier (UDI) and the device version, we have partnered with the FDA’s AccessGUDID database to ensure the highest quality and completeness of data, with unrivaled recency. 

OMNY Health’s Medical Device product offering linked with OMNY Health’s EHR data, can help device manufacturers and provider networks better understand and assist the patients they are servicing by examining: 

  • Medical Device use and trends 
  • Patient journeys and continuity of care
  • Impact of medical devices on clinical, functional, cost, and utilization outcomes
  • Safety/adverse event reporting
  • Providers who are interested in value-based contracting and making procurement decisions

Check out the Total Knee Replacement study utilizing the OMNY Health Medical Device product offering. 

Contact OMNY to learn more about how our Medical Device product offering will boost your real-world evidence generation.

Categories
Editorial

Social Determinants of Health: Generating Accurate Clinical Insights Using Real-World Data

Social Determinants

Recent innovations in healthcare analytics and patient-oriented AI demonstrate the power of leveraging real world data (RWD) to generate ecologically valid actionable insights for life sciences companies to improve patient lives and streamline new therapeutic advances. Such insights are essential for decision-making in health economics and outcomes research (HEOR) and in the clinical trial planning and implementation processes. However, the breadth, depth, and inclusivity of the data used to generate such insights can have a huge impact on both the accuracy and validity of any analyses. Various sources of bias, such as the lack of demographic and socioeconomic diversity in a cohort, can undermine the main benefit of using RWD to supplement life sciences research. To combat this, many researchers and providers have publicized the need for clinically-validated metrics that can be used to measure and quantify cohort-level bias and provide more transparency in the field.

Social Determinants of Health Data Account for Notable Variations in Clinical Outcomes

One commonly referenced set of measures that has received growing recognition is social determinants of health (SDoH) data – a set of criteria used to capture economic and social vulnerabilities across key domains. Various studies have estimated that accounting for SDoH variables, such as income level, housing security, transportation, gender identity, and race and ethnicity, can account for 40 – 60% of the variation in clinical outcomes and care patterns. A recent study examining Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) data illustrates this all too well. Researchers found that trial participants in the lowest-income trial sites had poorer blood pressure control and worse outcomes for some adverse cardiovascular events, even when treatment access and adherence were accounted for. The authors concluded that these results clearly illustrate “the importance of measuring and addressing socioeconomic context in [randomized controlled trials] RCTs.” The incorporation of these factors into studies leveraging RWD is just as important.  

United States Government Support for Clinical Research and RWD Inclusivity

Researchers are not the only ones promoting the importance of SDoH – the U.S. government is facilitating efforts to foster greater inclusivity in clinical trial participation across multiple fronts. The Food and Drug Administration has issued new guidelines about the use of RWD in clinical research, pointing to the utility of inclusive data sources to identify clinical trial participants. The Centers for Medicare & Medicaid Services (CMS) are also focused on health equity. At the end of 2023, CMS released an updated framework for health equity with a focus on the collection of interoperable, standardized SDoH. As of January 2024, CMS requires the screening of five SDOH domains for admitted hospital patients.  

Challenges with Obtaining and Utilizing SDoH Data

Despite the power of SDoH to create a more inclusive real-world environment for clinical trials and research analyses, patient-level SDoH data availability to pharmaceutical companies has been lacking. This is in large part due to barriers relating to extracting and aggregating relevant material. In typical healthcare systems, patient-level SDoH data are often difficult to expose and curate as the relevant information is buried in clinical codes and unstructured notes. However, the aforementioned efforts by various government entities have resulted in an exponential increase in the amount of patient-level SDoH data available in medical records – including increased use of structured surveys and other collection tools. 

Much of the SDoH data currently available in the RWD marketplace rely on a combination of 3-digit zip-code-level data and aggregated claims or credit data, which only provide inferred modeled proxies, not insight into actual patient-level information. Those that are able to derive SDoH variables through direct access to EHRs often face issues such as data lags, inconsistent data collection vehicles, and gaps in reporting. OMNY Health has the technology in place at the provider level creating a direct flow of data through the OMNY platform so that data is captured consistently with limited lag time. These unique integrated partnerships with large integrated delivery networks (IDNs) and specialty networks have enabled us to quickly capitalize on the growing availability of SDoH data in patient records.  

OMNY Health Top-tier SDoH Data Sets

OMNY Health is focused on creating a best-in-class SDoH data product to augment our existing EHR-derived, de-identified clinical data sets. Our ​​Social Determinants data offering is constructed from point-of-care documentation aggregated at the patient-encounter level. To ensure deep, multi-faceted coverage, we leverage multiple streams of information, including ICD-10 diagnostic codes, self-reported responses to standardized SDoH surveys, and estimated SDoH burden derived using research-grade, validated NLP models run on unstructured clinical notes.  

OMNY Health’s Social Determinants data offering, when integrated with our extensive clinical data sources, can help pharmaceutical companies and provider networks better help the patients they are serving and be more successful by informing: 

  • More accurate HEOR analyses 
  • Inclusive clinical trial planning and implementation 
  • Analysis of clinical trial results and differences in real-world populations 
  • The development of precision medicine treatments 
  • The understanding of the barriers to drug access and adherence and how to develop targeted programs to reduce those barriers 
  • Different disease severity and outcomes across populations and geographies 
  • Market access and pull-through strategies for contracting and drug promotion. 

SDoH data can offer insight into the everyday non-clinical factors that influence how individuals develop diseases, respond to treatments, and participate in clinical trials.  

Contact OMNY to learn more about how our SDoH data sets will boost your real-world evidence generation.

Categories
Editorial

Five Strategies To Boost Clinical Trial Diversity

Five Strategies To Boost Clinical Trial Diversity
Categories
News

OMNY Health and Datavant Announce Alliance to Accelerate Delivery of Real-World Data Between Healthcare Stakeholders to Enhance Clinical Research and Drug Development

 – Collaboration enables provider organizations to deliver de-identified, longitudinal data sets to life science companies and other trial sponsors –

– Real-world data offers unique insights in clinical research as drug developers focus on increasing equity in clinical trials and improving patient outcomes –

ATLANTA, GA, June 15, 2023 – OMNY Health, the premier healthcare ecosystem for facilitating compliant cross-industry health data sharing, and Datavant, the leader in helping organizations securely connect health data sets, have announced a collaboration agreement to accelerate the delivery of de-identified, real-world data (RWD) from provider organizations to clinical researchers and drug developers.

Under the agreement, provider organizations using Datavant’s software can now access OMNY Health’s suite of solutions to standardize, normalize, and de-identify their electronic health record (EHR) data into research-ready data sets, which can then easily be joined with other data sets utilizing Datavant’s suite of privacy-centric data connectivity tools. For researchers, the collaboration will provide access to a broad ecosystem of data from a diverse mix of provider organizations and patient populations. This will thoroughly support researchers’ analytical needs through compliant linkages to other available third-party data available in the Datavant ecosystem.

“This collaboration with Datavant puts us one step closer to eliminating unnecessary barriers in healthcare data fragmentation, which can be meaningful when it comes to impacting care,” said Dr. Mitesh Rao, Founder and CEO of OMNY Health. “By combining our organizations’ capabilities, we are creating efficiencies that provide clinical researchers and drug developers with data-backed information and insights that may help them address critical industry issues like diversity and equity in clinical research and improving patient outcomes.”

“The ability to combine Datavant’s data de-identification and connectivity capabilities with OMNY Health’s streamlined processes for rapidly creating research-ready data sets greatly expands the providers’ and researchers’ ability to follow the longitudinal patient journey across the full care continuum,” said Bob Borek, President and General Manager of the Life Sciences, Ecosystem, and Public Sector businesses at Datavant.“We are thrilled to collaborate with OMNY Health and look forward to the new insights our collaboration will bring to healthcare providers and researchers alike.”

Today, the OMNY Health platform includes longitudinal care journeys from a diverse group of provider organizations that deliver care to more than 50 million patients across all 50 states. All data is EHR-agnostic and represents more than 200 disease indications. OMNY Health’s curation process and provider group engagement surfaces richer clinical content and capabilities to prospectively collect data. This results in one of the largest and most extensive resources for deriving insights on real-world care in the United States.

About OMNY Health

OMNY Health connects patients, providers, and life sciences companies through data and insights to accelerate life-changing innovation. Our easy-to-use, secure platform enables life sciences organizations to engage in collaborative data and research partnerships efficiently, compliantly, and at scale. For more information, visit www.marketing-dev.omnyhealth.com or e-mail lifesciences@omnyhealth.com.

About Datavant

Datavant’s mission is to connect the world’s health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of patient health records across datasets. Learn more about Datavant at www.datavant.com.

###

 Media Contact:

Jennifer Ringler

(973) 647-5004

jringler@envhs.com

Categories
Editorial

Looking Back and Looking Forward: Top Five’s for 2021 and 2022

Happy New Year! We hope your family had a safe and healthy holiday season. 2021 was a busy year for us at OMNY Health, and we made great strides toward building out our ecosystem and supporting our mission of accelerating clinical innovation. To hit the highlights, we’ve put together two Top 5 lists, reminiscing some of our top 2021 achievements and looking ahead at some of the exciting opportunities coming in 2022.

Top 2021 Achievements

Commercial Launch of the OMNY Health Platform

In May, we announced the commercial launch of the OMNY Health Platform, a platform that endeavors to bring together the healthcare ecosystem, centered around data-driven clinical innovation. Since our launch, we have greatly expanded our commercial pipeline with a number of buyers actively evaluating our data offerings and utilizing our platform.  

Successful Completion of SOC 2 Type 1 Certification

In addition to our May product launch, we also achieved SOC2 Type 1 certification that same month. To achieve this our compliance and dev ops teams worked hard to put 25 policies and 90 related controls in place in the first part of the year. Being SOC2 compliant assures our partners that we have the infrastructure, tools, and processes to protect their data and to ensure that organizational controls and practices effectively safeguard the privacy and security of OMNY Health and partner data.  

Massive Integrated Dermatology Data Repository

One month later, we followed our commercial launch with the announcement of our national dermatology data repository. Initially launched with 7.5M+ patient lives, our overall data set now covers 40 of the 50 states, representing 22M+ patient lives, and includes care provided by over 47,000 providers. This represents nearly an 8x growth year over year in our data partnerships. In addition to our Base EHR data offering, we recently launched a product containing Surveys, Questionnaires, and Scores data. This unique offering sets us apart from other vendors, allowing researchers to capture outcomes values provided by providers and patients.  

Research Driven Support for Clinical Innovation

Our biostatistics/data science team has been deep in research mode all year. They have presented over a dozen posters and oral presentations at a number of large conferences this year, including ISPOR Europe, John Snow Labs NLP Summit, ISPE 37th International Conference, DIA Global Annual Conference, and ISPOR Annual Conference. All research has been based on data from our data repository and is helpful to demonstrate the value and utility of the data offerings we provide to customers. These presentations have broached an expansive cross-section of topics from COVID-19 to dermatology to natural language processing (NLP). And despite the holidays, our team spent much of the last few weeks in December hard at work drafting ten submissions for 2022’s ISPOR Annual Conference. 

Strengthened Intellectual Property Portfolio

In addition to one patent that was granted in 2020, we have two new patents that were granted in 2021. The patents granted were Unbiased Drug Selection using Distributed Ledger Technology (US 11,093,552) and Private Currency and Trade Engine (US 11,094,013). We are proud of our innovation team for getting these patents granted.  

Top 2022 Opportunities

Orthopedic and Ophthalmology Data Repository

We’ve been busy signing a number of orthopedic and ophthalmology practices to increase the patient lives and type of data covered in our data repository. Similar to how we built our large dermatology repository in 2021, we expect our numbers in orthopedics and ophthalmology to rival our dermatology data by mid 2022. In addition, we’ve been growing the number of signed health systems and will have broader coverage across additional service lines and specialties coming as well. 

Rapidly Expanding Team

We are growing, and we are hiring! In the last half of 2021, we saw our technical teams double in size, and we expect to almost double in all departments across the board in 2022. We are looking for talented and experienced people who can hit the ground running. We have a number of open roles available on our careers page  and invite you to please send good people our way.  

PandemicX Cohort

In December, we announced that we are one of the fifteen health tech startups accepted into the 2022 PandemicX Cohort. We will be working closely with U.S. Department of Health and Human Services and Mass Challenge Health Tech to use data to help solve the problems of health equity that have been brought to light by the pandemic. This aligns well with our mission, and we cannot wait to get started on this project. 

Data Expansion

In 2021, the introduction of our EHR data sets allowed us to become a major player in the industry. In 2022, we hope to expand those data sets even more with the addition of claims data. The augmentation of EHR data with claims data expands the opportunities and types of studies for which our data can be used. Throughout 2021, we have been building our capabilities for using natural language processing (NLP) to extract structured fields from unstructured notes data. This coming year, we expect to refine our processing and productize much of this data. 

Insights Beyond the Data

In the coming year, our roadmap includes a number of reports and dashboards that take a step beyond just data and into the realm of insights. We have been working closely with both sides of our ecosystem on some beta products that will allow users to make faster, more data-driven decisions. 

As you can see, we did some BIG things in 2021, but have even BIGGER things coming in 2022. Thank you to all of our partners, investors, and customers for your collaboration and support. We could not be where we are today without your help. And we look forward to continuing to build on these relationships in the coming year. Cheers to all the things to come in the New Year!

About the Author:
Dr. Mitesh Rao is the Founder and CEO of OMNY Health. A Board-Certified Emergency Medicine Physician, Dr. Rao has held executive roles at both Stanford’s and Northwestern’s health systems, where he helped lead patient safety and innovation. As a physician leader and executive, he has helped implement systems-level improvements for quality and safety in institutions across the country and overseas that have had lasting effects on care provision. Throughout his career, Dr. Rao has helped implement and scale new technologies within the clinical venue and serves as a mentor to multiple startups and accelerator groups across the country in order to help guide the development of innovative solutions that can sustainably impact patient care.

Categories
Editorial

ISPOR Annual 2021 Sheds Light on Impact of COVID-19

The International Society of Pharmacoeconomics and Outcomes Research (ISPOR) annual conference was held May 14-17, 2021. Although the conference assumed a virtual format like last year due to the pandemic, it did not disappoint, as it was filled with lots of thought-provoking content and engaged interactive discussions. As expected, many of the sessions were focused on COVID-19 and its impact on health economics and outcomes research (HEOR). Here are a few highlights:

The opening plenary session, which consisted of a diverse group of panelists from around the globe, focused on the response of various health systems on the COVID-19 pandemic. Topics of discussion included the strengths and weaknesses of health systems exposed by the pandemic, their swift and cohesive responses, and the collaboration with the pharmaceutical industry to help bring vaccines to market in record time. Other particularly interesting sessions on the first day included access and inequalities of COVID-19 vaccines, quantitative bias analysis in measuring treatment effects in real-world data, and the effect of the pandemic on the real-world evidence generation.

The second- and third-day plenary sessions generated several lively discussions on methodological issues of HEOR assessments in the wake of the pandemic and the new types of collaborations in the HEOR space between traditional players (e.g., regulators, payers, and providers) and new players (e.g., digital health startups and technology companies). General sessions and issue panels focused on various topics, including access to combination therapy in oncology, the application of public health data to evaluate COVID-19 interventions, the increasing dependence on real-world evidence, handling missing data in analysis, real-world data transparency, and machine learning methods as they relate to HEOR topics.

Finally, the poster sessions provided much valuable information on a diverse range of HEOR topics. OMNY Health contributed 4 posters based on the analysis of real-world data from our platform on the topics of psoriasis, pressure ulcers, identifying COVID-19 patients from unstructured clinical notes, and the COVID-19 hospitalized patient experience.

These though-provoking sessions that primarily revolved around COVID-19 provided interesting perspectives into the impact of the pandemic on the acceleration of innovation in healthcare. As we re-surface from the pandemic and additional data and discussions about the reach of healthcare and utilization of data evolve, it will be interesting to see where the remainder of 2021 takes us.

To learn more about this story and how to partner with OMNY Health, please contact us.

Categories
Product

Accelerate the Pace of Life-Changing Innovation

Hidden deep in healthcare data lies powerful insights and clinical revelations. Knowledge, that when shared with healthcare visionaries, can spark actions that will accelerate the pace of life changing innovations.  Curating this wealth of knowledge requires precise data handling and a sharp focus on balancing two important factors:  Patient Privacy and Care Innovation.  

OMNY Health’s technology solutions deliver immediate value to Life Sciences researchers by delivering standardized patient, encounter, notes, and supply data from a diverse set of providers in a secure cloud platform. With off-the-shelf data, dashboards, reports, and analytics available in a variety of formats and combinations, time to insights and decisions accelerate, so your team can focus on improving access to effective treatments and transforming the lives of patients. OMNY works closely with integrated delivery networks, community hospital systems, and even specialty practices to harmonize their data, enable custom analytics and create a real-word data pipeline. 

These clinical insights are shared with Life Sciences companies for use in expediting Research & Development, driving new therapy launches and accelerating commercialization strategies. And while providers and pharmaceutical innovators benefit significantly from the standardization and flow of useful data, the ultimate winners are the patients.

Here’s an example:

Working with 2 health systems, we uncovered insights that directly informed treatment decisions for Myasthenia Gravis, or MG, patients and powered pre-launch research for a new innovative MG drug . What’s more, we provided real-world context to understand MG therapy burden and barriers to care.

Healthcare data holds the promise of clinical innovation. OMNY can connect you with the quality data you need to inform and transform actions that will make a real difference in patients’ lives. The future of healthcare is accessible today.

 To learn more about this story and how to partner with OMNY Health, please contact us.

Categories
News

OMNY Health Launches Platform to Accelerate Life-Changing Innovations through Data-Driven Insights

Connects data from hospitals, health systems, specialty medical groups with life sciences researchers 

ATLANTA, May 6, 2021 /PRNewswire/ — OMNY Health (OMNY Inc.) today announced commercial availability of the OMNY Health Platform™,  a healthcare data-sharing solution that accelerates innovation by connecting the healthcare ecosystem with opportunities to connect anonymized data with researchers from life sciences organizations. Platform clients can use this data to develop new therapies, enhance treatment availability, and measure effectiveness.

The use of anonymized real-world treatment data to support life sciences companies’ decision-making across healthcare is not new. It is, however, often done without the direct involvement of healthcare providers — the originators of the information. The OMNY Health Platform offers provider organizations of all sizes the ability to participate in data-sharing partnerships with life sciences organizations to support research activities in an efficient and compliant manner.

“As a healthcare executive focused on patient safety and quality, I was often frustrated with our inability to efficiently partner with life sciences companies to help address patients’ treatment challenges and understand unmet needs,” said Mitesh Rao MD, CEO and Founder of OMNY Health. “OMNY Health provides a trusted, compliant solution for patients and providers to build transparent and secure data-driven relationships at scale and with minimal effort.”

The OMNY Health Platform centers on de-identified, normalized electronic health record data, enhanced with tokens that support links across the data ecosystem, all while preserving patient anonymity.  A diverse set of hospitals, health systems, and specialty provider organizations have already agreed to join the network, representing care delivered in more than 39 states and more than 10 million patient lives.

The platform contains more than 100 pre-packaged searchable and downloadable data offerings, aligned to strategic therapeutic areas, drug classes, and procedure groups.  The direct-from-source data on the platform cover both inpatient and outpatient care and all payer types. OMNY can also provide custom data cuts and analyses for life sciences researchers.  Insights from these data can help better understand unmet patient needs, design more efficient clinical trials, and inform strategies to address challenges in access to care.

The number of organizations opting to participate on the data sharing platform is rapidly growing, as are the types of data being made available.

“We focused on creating a flexible, scalable architecture that supports the diverse set of data needed by life sciences organizations to meet multiple use cases across the value chain, and one that could easily integrate into their workflows,” said Sean O’Brien, co-founder and Chief Technology Officer at OMNY.  “Time and budget constraints can hinder life sciences companies from getting the information needed for faster, more-effective decision-making.  Our platform specifically addresses these challenges.”

Solution demonstrations and studies showcasing the diverse data available via the OMNY Health Platform are scheduled to be presented during a variety of events this summer, including ISPOR, DIA, and ICPE.

About OMNY Health OMNY Health connects patients, providers, and life sciences companies through data and insights to accelerate life-changing innovation.  Our easy-to-use, secure platform enables life sciences organizations to engage in collaborative data and research partnerships efficiently, compliantly, and at scale.

The team at OMNY Health imagines a future of patient-centered and evidence-based care. We’ll achieve that mission through a seamless workflow of analysis-to-insight-to-decision-making based on a connected ecosystem of healthcare data and collaboration across the healthcare ecosystem.   

For more information visit www.marketing-dev.omnyhealth.com or e-mail:lifesciences@omnyhealth.com.

View full press release

Categories
Product

How OMNY Health™ Is Supporting the Fight Against MG

OMNY Health™ worked closely with an innovative pharmaceutical company to support the launch of its Myasthenia Gravis (MG) drug by providing data from two of its health system partners.

Compiling in-depth information from more than 30 of our partnered medical facilities, we delivered a snapshot of the real-world healthcare encounters and treatment experience for over 1,700 patients via a secure, de-identified dataset. The OMNY Health Insights professional services team delivered dashboards characterizing the patient journey from initial interaction points to ultimate diagnosis and treatment, a solution that the pharma company’s claims data supplier could not provide. 

Of note, the insights collected enabled deeper insights into both inpatient and outpatient settings, as well as the broad spectrum of medical specialists delivering the care. Not surprising, variation in care was identified across physician specialty.

Armed with this data, our customer has optimized access to its product for patients in need. The insights our team provided allowed their global rare disease experts to better understand patient journeys without compromising privacy. 

Funds from this engagement have already routed back to the participating health systems for reinvestment, empowering them to hire more staff, improve frontline staff salaries, address budget challenges, and invest in new medical equipment. 

To learn more about this story and how to partner with OMNY Health, please contact us.